Saint-Herblain (France), June 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease vaccine candidate, VLA15, were published in the peer-reviewed medical journal, The Lancet Infectious Diseases. These trials, as well as a third Phase 2 trial in pediatric participants, supported the design of the current pivotal Phase 3 trial, 'Vaccine Against Lyme for Outdoor Recreationists' (VALOR). Juan Carlos ...

Saint Herblain (France), May 31, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of Valneva's single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The European Commission (EC) will review the CHMP recommendation, and a decision on the marke ...

Valneva SE (NASDAQ:VALN) Q1 2024 Earnings Conference Call May 7, 2024 9:00 AM ET Company Participants Josh Drumm - VP, Global Investor Relations Thomas Lingelbach - President, CEO & Director Peter Buhler - CFO Conference Call Participants Max Herrmann - Stifel Rajan Sharma - Goldman Sachs Evan Wang - Guggenheim Samir Devani - RX Securities Limited Ed White - H.C. Wainwright & Co. Suzanne van Voorthuizen - Van Lanschot Kempen Maury Raycroft - Jefferies Josh Drumm Hello, and thank you for joining us to discu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 13(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

EXHIBIT 99.1 Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. Saint-Herblain (France), March 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ, moderate a roundtable on the Zika and chikungunya viruses, and participate in a panel discussion on efforts to eradicate chikungunya at the 24th World Vaccine C ...

Valneva SE (NASDAQ:VALN) Q4 2023 Results Conference Call March 20, 2024 10:00 AM ET Company Participants Joshua Drumm - Vice President of Investor Relations Thomas Lingelbach - President, CEO & Director Peter Buhler - Chief Financial Officer Conference Call Participants Max Herrmann - Stifel Maury Raycroft - Jefferies Evan Wang - Guggenheim Securities Ed White - H.C. Wainwright Nick Hallatt - Goldman Sachs Samir Devani - Rx Securities Joshua Drumm Thank you. Hello, and thank you for joining us to discuss Va ...

Valneva SE (NASDAQ:VALN) Q3 2023 Earnings Conference Call November 9, 2023 9:00 AM ET Conference Call Participants Good day and thank you for standing by. Welcome to the Valneva 9 Months 2023 Financial Results Call. [Operator Instructions]. Thank you for joining us to discuss Valneva's 9 months 2023 results and corporate update. It's my pleasure to welcome you today. In addition to our press release and analyst presentation, you can find our consolidated financial results for the 9 months ended September 30 ...

Valneva SE (NASDAQ:VALN) Q2 2023 Earnings Conference Call September 21, 2023 9:00 AM ET Company Participants Maury Raycroft - Jefferies Samir Devani - Rx Securities Simon Scholes - First Berlin Damien Choplain - Oddo BHF Evan Wang - Guggenheim Securities Suzanne Van Voorthuizen - VLK Max Herrmann - Stifel I would now like to turn the conference over to your speaker, Joshua Drumm, VP, Global Investor Relations. Please go ahead, sir. As always, I'm joined today by Valneva's CEO, Thomas Lingelbach; and CFO, Pe ...

Valneva SE (NASDAQ:VALN) Q1 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants Joshua Drumm - VP, IR Thomas Lingelbach - Chairman, President & CEO Peter Buhler - CFO Conference Call Participants Kevin Strang - Jefferies Edward White - H.C. Wainwright & Co Boran Wang - Guggenheim Securities Simon Scholes - First Berlin Rajan Sharma - Goldman Sachs Group Samir Devani - Rx Securities Limited Max Herrmann - Stifel, Nicolaus & Company Operator Good day and thank you for standing by. Welcom ...

EXHIBIT 99.1 Valneva Reports Full Year 2022 Results and Provides Corporate Updates Total revenues of €361.3 million in 2022 compared to €348.1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales and €29.6 million of COVID-19 vaccine sales €246.5 million of Other Revenues, primarily driven by revenue recognition related to previous COVID-19 vaccine supply agreements Strong cash position of €289.4 million at December 31, ...